Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Operating Leases (2021 - 2025)

Kezar Life Sciences' Operating Leases history spans 5 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, changed N/A, while the annual FY2024 figure was $2.3 million, 60.25% down from the prior year.
  • Operating Leases for Q3 2025 was $3.3 million at Kezar Life Sciences, down from $4.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.9 million in Q4 2022 and bottomed at $2.3 million in Q4 2024.
  • The 5-year median for Operating Leases is $4.0 million (2021), against an average of $4.6 million.
  • The largest annual shift saw Operating Leases soared 175.05% in 2022 before it crashed 60.25% in 2024.
  • A 5-year view of Operating Leases shows it stood at $3.2 million in 2021, then soared by 175.05% to $8.9 million in 2022, then plummeted by 33.99% to $5.9 million in 2023, then plummeted by 60.25% to $2.3 million in 2024, then skyrocketed by 40.11% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Operating Leases are $3.3 million (Q3 2025), $4.2 million (Q2 2025), and $5.0 million (Q1 2025).